Open AccessTHE INFLUENCE OF AWARENESS OF PATIENTS WITH POSTMENOPAUSAL OSTEOPOROSIS ABOUT THE MAGNITUDE OF THE FRAX 10-YEAR ABSOLUTE RISK OF FRACTURE ON THE DECISION TO START AND THE ADHERENCE TO ANTIOSTEOPOROTIC TREATMENT (INTERIM RESULTS OF «CRYSTAL» STUDY)
Author(s) -
Olga Lesnyak,
Е. Н. Хосева,
Л. В. Меньшикова,
Т. В. Антонова,
И. М. Ивыгина,
Е. В. Капустина,
I I Veytsman,
И. Б. Белоусова,
Е. И. Ситникова,
S. Yu. Shkireeva,
О. Б. Божко,
Natalya Bezlyudnaya,
L Kh Gilyazeva,
N Yu Kozhevnikova,
Yu. V. Titova,
Е. Н. Чикина,
Н. Н. Калинина,
Irina E. Prokhorova
Publication year - 2014
Publication title -
osteoporoz i osteopatii
Language(s) - English
Resource type - Journals
eISSN - 2311-0716
pISSN - 2072-2680
DOI - 10.14341/osteo201427-10
Subject(s) - frax , medicine , osteoporosis , absolute risk reduction , adverse effect , randomized controlled trial , physical therapy , osteoporotic fracture , bone mineral , confidence interval
To assess the influence of informing patients with postmenopausal osteoporosis about the their probability of 10-year absolute fracture risk calculated by FRAX tool on the patient ’s decision to start treatment and their adherence to therapy during 3 years of follow-up. Materials and Methods. Multicenter open randomized trial included 417 women (mean age 65.9 years). Patients of the 1 group (n=191) were informed about the value of their absolute risk of fracture by FRAX. Patients of the 2 group (the control; n=196) got usual advice and recommendations without calculating FRAX. All patients were recommended to take alendronate in a standard dose (70 mg a week) and calcium/vitamin D supplements. Results. During the first three months after initial visit 96.4% of patients started their treatment. The adherence to treatment at sixth month was 7% higher in the group 1; the compliance in the group 1 was 8% higher, than in the control group. 6.4% of patients developed adverse drug reactions, which led to cancellation of therapy in only 2.9% of patients.